Bio-Rad (BIO) Posts Q3 EPS of $1.38, Tops Estimates
More News related to BIO
- BioAlliance Pharma Presents Efficacy and Safety Preclinical Results for Its AMEP(TM) Anti-Invasive Biotherapy at The ESGCT Annual Congress in Hannover, November 21 to 25, 2009
- BioAlliance Pharma ranked as France's fastest growing company in the 2009 Deloitte Technology Fast 50(TM)
- Vernier and Bio-Rad to Offer Enhanced Solutions for Biotechnology Education
- Trading Outlook for Vermillion Inc. Issued by StockPreacher.com
- BioAlliance Pharma Presents Results for Its New Oral Chemotherapy Nanoparticle Innovation at the AAPS Annual Meeting in Los Angeles, November 8 to 12, 2009
More News related to Earnings
- Peet's (PEET) Moving Even Lower as Cowen Issues Mid-Day Downgrade
- RBC Downgrades Cephalon (CEPH) Following Cinquil Trial Results; Sees 'Little Momentum' Behind the Stock
- BMO Capital Downgrades Terra Industries (TRA) to Market Perform
- FTN Equity Downgrades Momenta Pharmaceuticals (MNTA) to Neutral
- Sterne Agee Downgrades Shoe Apparel Stores FINL & FL
Bio-Rad Laboratories, Inc. (NYSE: BIO) reports Q3 EPS of $1.38, versus the analyst estimate of $1.06. Revenue for the quarter was $461.10 million, which compares to the estimate of $435.62 million.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
